Silence Therapeutics (NASDAQ:SLN) Given New $45.00 Price Target at Morgan Stanley

Silence Therapeutics (NASDAQ:SLN) had its price objective decreased by Morgan Stanley from $49.00 to $45.00 in a research note published on Wednesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Other analysts also recently issued research reports about the stock. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. The Goldman Sachs Group decreased their price target on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a research note on Tuesday. BMO Capital Markets decreased their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, Silence Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN opened at $4.73 on Wednesday. The company has a market cap of $141.57 million, a P/E ratio of -3.01 and a beta of 1.05. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72. The firm has a 50-day simple moving average of $5.49 and a two-hundred day simple moving average of $11.53.

Hedge Funds Weigh In On Silence Therapeutics

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new position in Silence Therapeutics in the fourth quarter worth approximately $26,000. GAMMA Investing LLC grew its holdings in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares during the last quarter. Barclays PLC grew its holdings in Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after purchasing an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics in the fourth quarter worth $69,000. Finally, Virtus ETF Advisers LLC grew its holdings in Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after purchasing an additional 6,098 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.